Prosopagnosia, hereditary

Summary

Prosopagnosia, hereditary (MONDO:0012484) is a disease and 3 clinical trials. Top therapeutic interventions include oxytocin. A subtype of prosopagnosia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prosopagnosia, hereditary
Mondo ID	MONDO:0012484
MeSH	C537242
OMIM	610382
UMLS	C2931455
MedGen	419809
GARD	0010035
Is cancer (heuristic)	no

Also known as: congenital prosopagnosia · developmental prosopagnosia · hereditary prosopagnosia · hereditary prosopagnosia (disease) · prosopagnosia, hereditary

Disease family

This is a subtype of prosopagnosia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › agnosia › prosopagnosia › prosopagnosia, hereditary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02091817	EARLY_PHASE1	SUSPENDED	The Effect of Oxytocin on Face Perception
NCT04799340	Not specified	UNKNOWN	Computer-based Training of Face Recollection to Improve Face Recognition in Developmental Prosopagnosia
NCT05800782	Not specified	UNKNOWN	Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXYTOCIN	4	1